48303-2 |
Brilliant black BN leukotriene release |
MCnc |
WBC |
Pt |
Qn |
|
|
ACTIVE |
Brilliant black BN triggered leukotriene release [Mass/volume] by Leukocytes |
|
MIN |
DefinitionDescription |
|
|
pg/mL sLT |
|
|
|
|
|
|
ALLERGY |
|
48303-2 |
|
|
|
|
Both |
|
|
|
0 |
Brilliant black BN LR-mCnc |
|
|
|
N |
|
Allergen; Allergens; ALLERGY TESTING; CAST; Leukocytes; Level; LR; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL{sLT} |
|
|
|
0 |
48304-0 |
Glutamate leukotriene release |
MCnc |
WBC |
Pt |
Qn |
|
|
ACTIVE |
Glutamate triggered leukotriene release [Mass/volume] by Leukocytes |
|
MIN |
DefinitionDescription |
|
|
pg/mL sLT |
|
|
|
|
|
|
ALLERGY |
|
48304-0 |
|
|
|
|
Both |
|
|
|
0 |
Glutamate LR-mCnc |
|
|
|
N |
|
Allergen; Allergens; ALLERGY TESTING; c707; CAST; Glu; Glutamic acid; Leukocytes; Level; LR; Mass Concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL{sLT} |
|
|
|
0 |
48305-7 |
Coproporphyrin 1/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Coproporphyrin 1/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/g creatinine |
|
|
|
|
|
|
CHEM |
|
48305-7 |
|
|
|
|
Both |
|
|
|
0 |
Copro1/Creat Ur |
|
|
|
N |
|
Chemistry; Copro; Copro1; Coproporph; Coproporphyrin I; Coproporphyrins; CR; Crea; Creat; i; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Tetracarboxyl porphyrin; Tetracarboxylporphyrin; Tetracarboxylporphyrins; Tetracarboxyporphyrin; UA; UCr; UR; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
ug/g{creat} |
|
|
|
0 |
48306-5 |
Coproporphyrin 3/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Coproporphyrin 3/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/g creatinine |
|
|
|
|
|
|
CHEM |
|
48306-5 |
|
|
|
|
Both |
|
|
|
0 |
Copro3/Creat Ur |
|
|
|
N |
|
Chemistry; Copro; Copro3; Coproporph; Coproporphyrin III; Coproporphyrins; CR; Crea; Creat; III; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Tetracarboxyl porphyrin; Tetracarboxylporphyrin; Tetracarboxylporphyrins; Tetracarboxyporphyrin; UA; UCr; UR; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
ug/g{creat} |
|
|
|
0 |
48307-3 |
Didanosine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Didanosine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
48307-3 |
|
|
|
|
Both |
|
|
|
0 |
Didanosine SerPl-mCnc |
|
|
|
N |
|
ddI; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Videx |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
48308-1 |
DNA double strand Ab |
ACnc |
Body fld |
Pt |
Qn |
Farr |
|
ACTIVE |
DNA double strand Ab [Units/volume] in Body fluid by Farr method |
|
MIN |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
SERO |
|
48308-1 |
|
Farr |
|
|
Both |
|
|
|
0 |
dsDNA Ab Fld Farr-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Deoxyribonucleic acid; DNA binding ab; ds; dsDNA; dsnda; Fl; Fld; FLU; Fluid; Native DNA; N-DNA; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Stranded; Strnd |
2.7 |
2.21 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
48309-9 |
BK virus DNA |
NCnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
BK virus DNA [#/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
48309-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
BKV DNA # Spec NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; BKV; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.73 |
2.21 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
4831-4 |
HLA-B40 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-B40 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4831-4 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B40 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48310-7 |
Influenza virus A |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Influenza virus A [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48310-7 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
FLUAV Spec Ql Cult |
|
|
|
N |
|
Avian influenza; Bird flu; C&S; Cult; Cultures; FLUA; FLUAV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48311-5 |
Lysosomal enzymes screen |
Prid |
Bld |
Pt |
Nom |
|
|
ACTIVE |
Lysosomal enzymes screen [Identifier] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
48311-5 |
|
|
|
|
Both |
|
|
|
0 |
Lysosomal Enzymes Scn Bld |
|
|
|
N |
|
Blood; Chemistry; Enz; Enzyme; Identity or presence; Lysosomal Enzymes Scn; Nominal; Point in time; Random; Scn; Scr; Scrn; WB; Whole blood |
2.21 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
48312-3 |
Yersinia enterocolitica O:5 Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Yersinia enterocolitica O:5 Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
48312-3 |
|
Aggl |
|
|
Both |
|
|
|
0 |
Y entero O:5 Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr; Y entero O:5; Y enterocol; Y enterocolitica |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
Changed O5 to O:5 based on currently recommended nomenclature for the Yersinia enterocolitica serogroups [PMID: 22019131] |
0 |
48313-1 |
Yersinia enterocolitica O:9 Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Yersinia enterocolitica O:9 Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
48313-1 |
|
Aggl |
|
|
Both |
|
|
|
0 |
Y entero O:9 Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr; Y entero O:9; Y enterocol; Y enterocolitica |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
Changed zero to O in component; Changed O9 to O:9 based on currently recommended nomenclature for the Yersinia enterocolitica serogroups [PMID: 22019131] |
0 |
48314-9 |
Leishmania mexicana Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Leishmania mexicana IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
48314-9 |
|
IF |
|
|
Both |
|
|
|
0 |
L mexicana IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L mexicana; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
48315-6 |
Leishmania mexicana Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Leishmania mexicana IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
48315-6 |
|
IF |
|
|
Both |
|
|
|
0 |
L mexicana IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L mexicana; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
48316-4 |
Leishmania tropica Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Leishmania tropica IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
48316-4 |
|
IF |
|
|
Both |
|
|
|
0 |
L tropica IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L tropica; L tropicalis; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
48317-2 |
Leishmania tropica Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Leishmania tropica IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
48317-2 |
|
IF |
|
|
Both |
|
|
|
0 |
L tropica IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; L tropica; L tropicalis; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
48318-0 |
Cat hair+Cat epithelium Ab.IgE.RAST class |
ACnc |
Ser |
Pt |
Ord |
|
|
DEPRECATED |
Deprecated Cat hair + Cat dander IgE Ab RAST class in Serum |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
48318-0 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated Cat Hair+Epith IgE RAST Ql |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Epithelia; Feline; Felis domesticus; IgE RAST; Immune globulin E; Immunoglobulin E; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.36 |
2.21 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
48319-8 |
glipiZIDE |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
glipiZIDE [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48319-8 |
|
|
|
|
Both |
|
|
|
0 |
glipiZIDE Spec Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Glucotrol; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4832-2 |
HLA-B44(12) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B44(12) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4832-2 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B44(12) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48320-6 |
glyBURIDE |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
glyBURIDE [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48320-6 |
|
|
|
|
Both |
|
|
|
0 |
glyBURIDE Spec Ql |
|
|
|
N |
|
DiaBeta; DRUG/TOXICOLOGY; Drugs; Glynase; Micronase; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48321-4 |
TOLBUTamide |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
TOLBUTamide [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48321-4 |
|
|
|
|
Both |
|
|
|
0 |
TOLBUTamide Spec Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Novo-butamide; Ordinal; Orinase; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48322-2 |
acetoHEXAMIDE |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
Acetohexamide [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48322-2 |
|
|
|
|
Both |
|
|
|
0 |
acetoHEXAMIDE Spec Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Dymelor; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48323-0 |
TOLAZamide |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
TOLAZamide [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48323-0 |
|
|
|
|
Both |
|
|
|
0 |
TOLAZamide Spec Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Tolinase; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48324-8 |
chlorproPAMIDE |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
chlorproPAMIDE [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48324-8 |
|
|
|
|
Both |
|
|
|
0 |
chlorproPAMIDE Spec Ql |
|
|
|
N |
|
Diabinese; DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48325-5 |
Glimepiride |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Glimepride [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
None detected |
|
|
|
|
|
DRUG/TOX |
|
48325-5 |
|
|
|
|
Both |
|
|
|
0 |
Glimepiride SerPl Ql |
|
|
|
N |
|
Amaryl; DRUG/TOXICOLOGY; Drugs; Glista OD; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |